LAUSR

Fibromyalgia syndrome (FMS) is a non-autoimmune rheumatological disorder characterized by chronic widespread pain, and often tenderness, with additional symptoms such as fatigue, lack of sleep, anxiety, and cognitive problems which are considered significant features in this syndrome. Diabetes mellitus (DM) is a chronic metabolic disorder characterized by hyperglycemia that develops as a consequence of insulin deficiency [type1 DM T1DM)] and/or insulin resistance [type2 DM (T2DM)]. A descriptive cross-sectional study was conducted at Endocrine and Rheumatology unit at Baghdad Teaching Hospital during the period from November 2021 till April 2022. A total random sample of 200 Iraqi patients with Diabetes mellitus type 2 diagnosed according to the WHO criteria for diagnosis of diabetes mellitus (females 128 and males 72) and a total random sample of 200 healthy persons (126 females and 74 males) were involved in this study as controls. A special questionnaire designed for the purpose of the study was used for recording information from the patients and controls, which include demographical data for both group in addition information about current treatment for DM and duration of disease. The 2016 revision of American College of Rheumatology (ACR) criteria was used for the diagnosis of FMS. There was increase in the risk of developing FMS among diabetes mellitus patients compared to normal individuals (31% vs. 14.5%). Moreover, widespread pain, symptom severity score, and depression were significantly higher [P. Value (0.012, 0.007, 0.019)] respectively among diabetes mellitus patients compared to healthy individuals. It was found that there was a significant increase of having HbA1c increased by 1.38 among fibromyalgia patients compared to healthy individuals. The prevalence of fibromyalgia among the studied sample with type 2 diabetes mellitus was high and there was correlation between the prevalence rate of FMS and poor DM control. Disclosure S. Salman: None. H. Abdali: None.